Upgrade to SI Premium - Free Trial

Mylan (MYL) PT Raised to $44 at BofA/Merrill Lynch Following Generic Estrace Cream Approval

January 4, 2018 8:08 AM
BofA/Merrill Lynch raised its price target on Mylan (NASDAQ: MYL) to $44.00 (from $41.00) while maintaining a Neutral rating following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change

Next Articles